MOUSE EMBRYONIC STEM CELLS EXPRESS FUNCTIONAL TOLL LIKE RECEPTOR 2 by Taylor, Tammi M.
 MOUSE EMBRYONIC STEM CELLS EXPRESS FUNCTIONAL TOLL LIKE  
RECEPTOR 2 
 
 
 
 
 
 
 
 
Tammi M. Taylor 
 
 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Microbiology and Immunology 
Indiana University 
 
 
February, 2010 
 
  
ii 
 
Accepted by the Faculty of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
                                                                                           
 
 
 
___________________________ 
Hal E. Broxmeyer, PhD Chair 
 
 
___________________________ 
Janice S. Blum, PhD 
Doctoral Committee 
 
___________________________ 
Alexander L. Dent, PhD 
 
December 11, 2009 
___________________________ 
Harikrishna Nakshatri, PhD 
 
 
___________________________ 
Mervin C. Yoder, MD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iii 
DEDICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I would like to dedicate this to my father Emmitt Monroe Taylor, my uncle James Ivory, 
and friend L.C. Tennin III. I know you are the angels watching over me each day. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iv 
ACKNOWLEDGEMENTS 
 
I would like to first and foremost thank my mentor Dr. Hal E. Broxmeyer, who 
has supported me since I started here the summer of 2003 as a Master’s student in the 
Bridges to Doctorate Program. Without your support and belief that this program is 
fundamental to helping underrepresented minorities gain the opportunity to acquire a 
higher education in the sciences I would not be where I am today. I would like to thank 
you for your guidance, support, and patience with me while working in your laboratory. I 
will always remember your advice, guidance, and unique ways of mentoring. I have been 
honored to work under your guidance and thank you for letting me do a project that truly 
interested me. 
 I would also like to thank other members of my committee. Drs. Janice S. Blum, 
Alexander L. Dent, Harikrinshna Nakshatri, and Mervin C. Yoder for all of your 
guidance, technical advice, support, and encouragement.  
I would like to give a special thanks and appreciation to my current and past lab 
members for overall team support especially Dr. Young-June Kim, Dr. Hee-Don Chae, 
Dr. Sunanda Basu, Dr. Tim Campbell, and Xuan Ou for helping me decide which 
avenues to take with my project, proofreading of manuscripts, and experimental advice. I 
would also like to thank past members Dr. Wen Tao and Dr. Evelyn Guo for teaching me 
all the techniques that I learned in the lab and for their guidance and friendship. Personal 
thanks goes to all current labmates in Dr. Broxmeyer and Dr. Pelus lab: Scott Cooper, 
Charlie Mantel, John Kinzfogl, Sara Rohrabaugh, Xuan Ou, HeeDon Chae, Dr.Ying Liu, 
  
v 
Guo Hangoc, Dr. Pratibha Singh, John Hoggatt, and Pamela Ruffin for your friendships 
and support.  
Other faculty in the department for support and guidance include Dr. Janice S. 
Blum who has been a friend, mentor, and a colleague. I appreciate all of your helpful 
advice and support throughout this process. I would like to thank the Derbigny lab, 
Kristen Hosey, Phatia Wells, Kathryn Tomey, and Dr. Wilbert Derbigny. You taught me 
a lot and I truly appreciate you taking the time out to show me techniques, and for being 
friends and collegues throughout this process. Thank you to Drs. Xin Yuan Fu, Randy 
Brutkiewicz, Paul Ardayfio, Ann Kimble-Hill, and Akira Moh for all of your positive 
energy, words of encouragement, advice, and support. Also thank you to the late Dr. 
Richard Haak who was very supportive of me and helpful in teaching me how to read 
scientific journals while taking my classes and telling me the importance of interpreting 
and understanding data, and proofreading my grant applications.  
I would thank current and past members of the former Walther Oncology Center 
and Microbiology and Immunology Department, especially Cindy Booth, Audry Carson, 
Trisha Clark, April Maines, Janis Stringer, and Sandra Wilson. You all were so valuable 
to me and thanks for your administrative help and advocacy. I would also like to thank 
my Bridges/IUSM coordinator Dr. Joseph Cameron. Thanks for recommending me for 
this program and your words of wisdom, encouragement, and continued support. Thanks 
also to other students Tabitha Hardy, Jeremy Lott, Phatia Wells, Pamela Ruffin, Kristen 
Hosey, Tanya Robinson, Carla Mangum, and Tamika Collins for your friendship. You 
  
vi 
taught me a lot and also motivated and inspired me and I wish you all well and much 
success.  
Thanks to my friends Tamara Buckner, LaTesia Johnson, Tracy Morris, and 
Crystal Lane for their love and support throughout this process. Finally, my most 
heartfelt thanks goes to my mother, Victoria Taylor, my sisters Tracey and Tina Taylor, 
my brothers Emmitt and Erwin Taylor, my Uncle Vernon Ivory, Aunt Tina Conner, 
cousin Felicia Casey, Angel Byrd, Uncle Nod Ivory, and Richard Smith for their 
unconditional love, support, motivational speeches, constant praying, monies, visits, and 
encouragement, throughout my graduate training. Lastly, thanks God for your unending 
love, favor, and support, which have helped me tremendously during this time. 
 
 
 
 
 
 
 
 
 
 
 
 
  
vii 
ABSTRACT 
 
Tammi M. Taylor 
 
MOUSE EMBRYONIC STEM CELLS EXPRESS FUNCTIONAL TOLL LIKE 
RECEPTOR 2 
Embryonic stem cells (ESCs) are unique in that they have potential to give rise to every 
cell type of the body. Little is known about stimuli that promote mouse (m)ESC 
differentiation and proliferation. Therefore the purpose of this study was to determine the 
role of Toll Like Receptor (TLR) ligands in mESCs proliferation, survival, and 
differentiation in the presence of Leukemia Inhibitory Factor (LIF). We hypothesized that 
TLRs are expressed and functional, and when activated by their ligand will induce 
survival, proliferation, and prevent differentiation. In this study, mESC line E14 was used 
to determine the expression of TLRs at the mRNA level and three mESC lines, R1, 
CGR8, and E14, were used to determine cell surface protein levels. We found expression 
of TLRs 1, 2, 3, 5, and 6 at the mRNA, level but no expression of TLRs 4, 7, 8 and 9 in 
the E14 mESC line. We confirmed the presence of TLR-2 but not of TLR-4, protein on 
the cell surface using flow cytometric analysis for all three cell lines. We focused our 
studies mainly on TLR-2 using the E14 cell line. Pam3Cys, is a synthetic triacyl 
lipoprotein and a TLR-2 ligand, which induced a significant increase in mESC 
proliferation on Days 3, 4, and 5 and enhanced survival of mESC in a dose dependent 
manner in the context of delayed addition of serum. All the latter experiments were 
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performed in triplicate and student T-test was performed to establish significant 
differences. Next, we demonstrated functionality of TLR-2 via the MyD88/IKK pathway, 
where MyD88 was expressed and IKKα/β phosphorylation was enhanced. This was 
associated with increased NF-κB nuclear translocation upon activation by Pam3Cys. 
Finally, we showed that there were no changes in expression of mESCs markers Oct-4, 
KLF-4, Sox-2, and SSEA-1, thus illustrating that the mESCs may have remained in a 
pluripotent state after activation with the TLR-2 ligand in the presence of LIF. These 
results demonstrate that mESCs can respond to microbial products, such as Pam3Cys, and 
can induce proliferation and survival of the mESCs. This finding expands the role of 
TLRs and has some implications in understanding embryonic stem cell biology.  
  
    Hal E. Broxmeyer, PhD, Chair 
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 INTRODUCTION 
 
Survival of an organism depends on how prompt its innate immune system responds to an 
outside pathogen. The innate immune system is the first line of defense and is made up of 
myeloid cells. Myeloid cells include macrophages, neutrophils, and dendritic cells. 
Pathogen Associated Molecular Particles (PAMPs) are recognized by a Toll Like 
Receptor (TLR) on the surface of lymphoid cells and induce maturation and 
differentiation of myeloid cells (Nagai, Garrett et al. 2006).    
Previous studies have shown TLRs to couple adaptive and innate immunity via 
lymphoid cells (Iwasaki and Medzhitov 2004). Lymphoid cells, include bone marrow 
derived B, thymus derived T, and Natural Killer (NK) cells. These cells are replenished 
by hematopoietic stem cells in the bone marrow (Kondo, Weissman et al. 1997). Stem 
cells are unique cells in the body formed during gestation, and are capable of self 
renewal. Embryonic (ES), fetal or adult stem cells preserve this unique quality. Stem cells 
can also give rise to multipotent progenitors that help replenish the hematopoietic and 
immune system, and other cell types of the body. They are products of ex-vivo culture of 
the blastocyst. 
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Embryonic Stem Cells 
Embryonic Stem (ES) cells have the unique ability to self renew and differentiate into 
derivatives of all three germ layers in vivo and in vitro (Friel, van der Sar et al. 2005). 
The three germ layers are ectoderm, mesoderm, and endoderm (Figure 1). ES cells are 
derived from the inner cell mass of the blastocyst (Evans and Kaufman 1981; Martin 
1981; Axelrod 1984; Wobus, Holzhausen et al. 1984; Doetschman, Williams et al. 1988; 
Smith 2001). The blastocyst consists of an outer cell layer called the trophoblast that give 
rise to the placenta, and an inner cell layer called the inner cell mass that gives rise to all 
tissues of the body (Friel, van der Sar et al. 2005). Scientists isolated cells from this 
region in the mouse blastocyst and were able to maintain these cells in culture on 
gelatinized plates with feeder layers (Mintz and Illmensee 1975). A factor found in the 
feeder layer was identified that prevented differentiation and promoted stem cell self 
renewal of mouse ES cells (Martin and Evans 1974; Evans and Kaufman 1981; Martin 
1981). Today this factor is known as Leukemia Inhibitory Factor (LIF). LIF allows 
murine ES cells to grow in the absence of a feeder layer (Smith, Heath et al. 1988; 
Williams, Hilton et al. 1988; Friel, van der Sar et al. 2005).  Human ES cells do not 
respond to LIF. Important unknowns are finding the factors that induce and maintain self 
renewal of human ES cells.     
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Figure 1. Stem Cell Hierarchy adapted from (Wobus and Boheler 2005). mES cells come  
 
from the inner cell mass of the blastocyst and can give rise to every cell type of the body.  
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Leukemia Inhibitory Factor 
LIF is a member of the Interleukin (IL)-6 family of cytokines.  The LIF receptor (R)  
consists of LIF-Rβ and the receptor gp130 (Figure 2). The binding of LIF to its receptor 
on mES cells activates two major pathways, the Janus tyrosine associated kinase (JAK) - 
signal transducer activator of transcription 3 (STAT-3) Pathway and the SHP2-ERK 
Pathway (Figure 2) (Burdon, Chambers et al. 1999; Burdon, Stracey et al. 1999). LIF 
binding to LIF-Rβ activates the JAKs which phosphorylate the Src Homology 2 (SH-2) 
domain of its downstream target, STAT-3. Once STAT-3 is phosphorylated it undergoes 
autophosphorylation and forms a STAT-3 homodimer. The STAT-3 dimer then 
translocates to the nucleus and binds to DNA binding sites of genes which control murine 
ES cell self -renewal (Friel, van der Sar et al. 2005). 
Another pathway that is activated by LIF is the SHP2-ERK pathway via the 
gp130 receptor. The LIF-gp130R activates the RAS/MAPK pathway. SHP2 associates 
with Gab1, which causes the activation of Ras which induces the transactivation of 
MAPKs and ultimately ERK phosphorylation. This pathway is thought to lead to 
differentiation of murine ES cells (Burdon, Stracey et al. 1999; Burdon, Smith et al. 
2002). 
A recent report has shown that mesenchymal stem cells which give rise to bone 
cartilage, adipose tissue, and chondrocytes can remain in an undifferentiated/ 
proliferating state when Pam3Cys is bound to its receptor TLR-2 in these cells (Pevsner-
Fischer, Morad et al. 2007). This is an important finding because in murine ES cells the 
activation of the MAPK/ERK pathway is thought to promote differentiation. 
  
6 
Figure 2. LIF/STAT3 Paradigm for ES cell Self Renewal. Some parts of the Figure were 
adapted from (Friel, van der Sar et al. 2005). LIF activates the JAKs which then activates 
STAT3 and forms a homodimer which activates expression of Nanog and Oct-4 genes. 
TLRs may activate the Gab1-Shp2 MEK/ERK pathways.  
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Previous studies have shown that activation of gp130 Rβ can elicit production of 
IL-6, TNF-α, and IL-11 (Hilton, Hilton et al. 1994; Friel, van der Sar et al. 2005; Jenkins, 
Roberts et al. 2005), which are cytokines produced in response to activation by TLRs. 
The IL-6 cytokine family has a role in the biological activities of multiple hematopoietic 
lineages and helps to maintain pluripotency of mouse (m) ES cells (Burdon, Chambers et 
al. 1999). For example, they can stimulate the production of immature hematopoietic 
progenitor cells (HPC) when used in synergy with stem cell factor (SCF) and interleukin 
(IL)-3 (Dexter, Allen et al. 1978; Jenkins, Roberts et al. 2005) and directly stimulate 
megakayocytes to become functionally mature. The binding of IL-6 to the gp130 subunit 
induces gp130 homodimerization which leads to activation of JAKs (Heinrich, Behrmann 
et al. 1998). This ultimately leads to the phosphorylation of STAT-1 or STAT-3 
(Gerhartz, Heesel et al. 1996).  
  Studies have shown TLR2 activation can lead to an increased production of IL-6 
and TNF-α in macrophage cells. This cytokine production will be used as one means to 
determine if TLR-2 is functional in mES cells in our studies.  
 
Self Renewal Markers 
There are several mouse/human ES cell self renewal markers that are distinct in 
undifferentiated ES cells. They include Nanog, Oct 4, and Sox 2 (Niwa, Miyazaki et al. 
2000; Avilion, Nicolis et al. 2003; Sato, Meijer et al. 2004; Friel, van der Sar et al. 2005).  
Mouse ES cells in un-differentiated states also express distinctive markers. These include 
an isozyme of alkaline phosphatase and SSEA-1. (Solter and Knowles 1978; Wobus, 
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Holzhausen et al. 1984; Thomson, Itskovitz-Eldor et al. 1998; Reubinoff, Pera et al. 
2000; Reubinoff, Pera et al. 2001; Xu, Inokuma et al. 2001; Henderson, Draper et al. 
2002; Friel, van der Sar et al. 2005). Oct-4 and Sox-2 but not Nanog are thought to be 
regulated by the transcription factor STAT-3 (Niwa, Burdon et al. 1998; Thomson, 
Itskovitz-Eldor et al. 1998; Pesce, Anastassiadis et al. 1999; Friel, van der Sar et al. 
2005). Nanog is downstream of the transcription factor Oct-4, and they both play a 
critical role in murine ES cell self renewal (Niwa, Miyazaki et al. 2000; Friel, van der Sar 
et al. 2005). Although the expression of these markers are considered one way to 
determine a non-differentiated state, the best way to determine non-differentiated state is 
putting the ES cells back into a blastocyt to develop into a mouse, or place the cells into a 
mouse to for teratomas.  
STAT-3 activation is not involved in TLR activation pathway in macrophages 
therefore this pathway was not studied in ES cells (Hu, Chen et al. 2007). The regulation 
of STAT-3 is critical in the homeostasis of hematopoiesis because STAT-3 when hyper-
activated can act as an oncogene (Bromberg, Wrzeszczynska et al. 1999).  Previous data 
has shown that STAT-3 plays an important role in the homeostasis of the undifferentiated 
and differentiated states of murine ES cells by activating ES cell self renewal marker Oct-
4 (Niwa, Burdon et al. 1998; Friel, van der Sar et al. 2005; Guo, Mantel et al. 2008). 
 
Toll-Like Receptor Pathway 
Toll-Like Receptors (TLRs) play a critical role in innate and adaptive immune 
responses against microbial pathogens (Akira, Takeda et al. 2001; Kambris, Hoffmann et 
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al. 2002; Beutler, Hoebe et al. 2003; Gangloff, Weber et al. 2003; Beutler, Hoebe et al. 
2004; Hoebe, Janssen et al. 2004; Beutler, Jiang et al. 2006). Today there are ten TLRs 
reported in humans and 12 TLRs reported in mice (Takeda and Akira 2005). They 
include TLR-1-10 in humans and TLR1-9, RP105/11, MD1/12, and MD2/13 in the 
murine system. TLR ligands better known as PAMPs include lipopolysaccharides (LPS) 
of Gram negative bacteria such as Salmonella or Escherichia coli which activate TLR-4 
(Figure 3) (Poltorak, He et al. 1998; Hoshino, Takeuchi et al. 1999). Lipoprotein, 
lipopeptides, and peptidoglycan of Gram positive bacteria are recognized by TLR-2. 
TLR-2 forms a TLR-1/2 and or 2/6 heterodimer which recognizes triacyl and diacyl 
lipoproteins respectively (Figure 3 and 4) (Takeuchi, Hoshino et al. 1999; Ozinsky, 
Underhill et al. 2000; Takeuchi, Kaufmann et al. 2000; Takeuchi, Sato et al. 2002). 
Pam3Cys is a synthetic triacyl lipoprotein and known activator of the TLR-2/1 
heterodimer (Shimizu, Kida et al. 2008). 
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Figure 3. Toll Like Receptor Pathway. Some parts of this figure were adapted from 
(Naumann 2000; Kawai and Akira 2005).  TLR-1 and TLR-2 form a heterodimer which 
is triggered by lipoproteins such as Pam3Cys, while TLR-6 and TLR-2 form a 
heterodimer that is activated by diacyl lipoproteins. LPS is the PAMP that triggers TLR-4 
to illicit an immune response. 
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Figure 4. TLR-2 mediated signaling pathways adapted from (Arbibe, Mira et al. 2000; 
Naumann 2000; Kawai and Akira 2005; Kawai and Akira 2006). Ligands bind to 
heterodimers TLR-1/2, and TLR-2/6. Triacyl lipoproteins bind TLR-1/2 and Diacyl 
lipoproteins bind to TLR-2/6. They both mediate their activities through the adaptor 
molecules MyD88 and TIRAP, and recruit IKK which phosphorylates NF-κB and cause 
it to translocate to the nucleus.  
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TLR stimulation by PAMPs trigger signaling cascades that require intracellular 
adaptive proteins such as myeloid differentiation primary response protein 88 (MyD88), 
Toll Interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon-beta 
(IFN-β) also known as TRIF, and Interleukin 1 receptor associated kinase (IRAK) 
(Figure 3 and 4) (Ferrandon, Imler et al. 2004; Takeda and Akira 2005). Activation of 
most TLRs induce the production of cytokines via the MyD88 pathway, excluding TLR-3 
which uses a MyD88-independent/TRIF pathway (Oshiumi, Matsumoto et al. 2003; 
Yamamoto, Sato et al. 2003). This leads to the activation of transcription factors such as 
activating protein 1 (AP-1), nuclear factor kappa-B (NF-κB), and interferon regulatory 
factors (IRFs) (Figure 4).  
 
Nuclear Factor of Kappa light polypeptide gene enhancer in B cells 
Nuclear factor kappa B (NF-κB) is a Rel family transcription factor composed of 
homo and heterodimers such as p50 and p65 subunits (Arbibe, Mira et al. 2000) (Figure 
4). NF-κB plays an important role in mammalian immunity and is activated by TLRs 
(Rosetto, Engstrom et al. 1995). TLRs initiate this pathway leading to NF-κB activation 
via signals through MyD88, IRAK, and TNF receptor associated factor -6 (TRAF6) 
adapator protein molecules (Arbibe, Mira et al. 2000; Bowie and O'Neill 2000; Irie, Muta 
et al. 2000) (Figure 4). The inactive form of NF-κB is a cytoplasmic heterodimer that 
consist of p50 and p65 subunits (Arbibe, Mira et al. 2000). Upon TLRs activation, IκB 
kinases (IKKs) are activated. IκB, the NF-κB inhibitor is degraded thus allowing NF-κB 
to translocate to the nucleus to mediate transcriptional gene activation (Mercurio, Murray 
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et al. 1999; Zandi and Karin 1999; Arbibe, Mira et al. 2000; Arsura, Mercurio et al. 2000) 
(Figure 4).   
Previous studies have shown NF-κB can induce tissue repair genes, inflammation, 
and neutrophil-specific chemokines in mouse embryonic fibroblasts and macrophage 
cells that are in a necrotic state (Li, Carpio et al. 2001). Therefore, it is thought that the 
triggering of NF-κB by TLRs may play a role in survival of the ES cells. Thus, we 
performed survival assays to determine if TLR activation can enhance survival of mES 
cells. 
Previous studies have shown TLRs 2 and 4 to be expressed in human 
hematopoietic progenitor cells and when stimulated with their ligands, to help replenish 
cells of the innate immune system in vitro (Banchereau and Steinman 1998; Nagai, 
Garrett et al. 2006).  Previous studies have also shown that mesenchymal stem cells 
(MSC) express all TLRs except 9 and when stimulated with their ligands prevent 
differentiation of MSCs into chondrocytes, adipose tissue, and cartilage, thus causing an 
increase in MSC proliferation in their non-differentiated state (Pevsner-Fischer, Morad et 
al. 2007). It was this information that interested us in studying a role for TLRs and their 
ligands in ES cell function. Activation of TLRs can promote the production of multiple 
cytokines and chemokines at a transcriptional level thus influencing the adaptive immune 
response (Figure 4). Some cytokines and chemokines whose secretion is induced by 
TLRs, are not produced or expressed only at low levels in the conditioned media of 
undifferentiated E14 ES cells. This includes TNF-α, and IL-6. (Guo, Graham-Evans et al. 
2006). Therefore in the current studies, the expression of these cytokines and 
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transcription factors via the IKK-αβ/NF-κB signaling pathway upon TLR stimulation was 
performed to determine the functionality of specific TLRs in mES cells  
 
Cytokines IL-6 and TNF-α 
IL-6 is a member of the IL-6 cytokine family and elicits a response via the gp130 
receptor-beta (Rβ) subunit.  Once IL-6 binds to its soluble IL-6 receptor-alpha (Rα) 
subunit, gp130 homodimerizes and activates the JAKs. JAKs then activate STAT-1 or 
STAT-3 (Gerhartz, Heesel et al. 1996). Previous studies have shown  that homeostasis of 
STAT-3 activation plays a role in mediating the cellular production of immature or 
committed hematopoietic progenitors, and is regulated by IL-6 production (Jenkins, 
Roberts et al. 2005; Chung, Park et al. 2006; Jenkins, Roberts et al. 2007). Previous 
reports have shown that in the absence of IL-6 signaling there is a decrease in STAT3 
hyper-activation and abnormal lymphopoiesis. Previous reports also have shown that if 
IL-6 is deleted in mice there are abnormalities of both immature and committed 
progenitors from multiple lineages from the spleen and bone marrow (Dexter, Allen et al. 
1978; Zipori 1989; Zipori 1990; Zipori 1992; Bernad, Kopf et al. 1994). IL-6 plays a role 
in mediating pathological hematopoietic and lymphoid responses by STAT-3 hyper-
activation (Jenkins, Roberts et al. 2007). 
 The over expression of IL-6 could lead to abnormalities i.e. tumorgenesis and 
human lymphoproliferative and myeloproliferative diseases, including multiple myeloma 
(MM), non-Hodgkin’s lymphoma (NHL), and acute myeloid leukemia (AML) which all 
display STAT3 deregulated activation (Jenkins, Roberts et al. 2007). We considered it 
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important to determine the role of TLRs in mESC differentiation, survival/proliferation 
and self renewal. Some TLRs are capable of inducing the production of inflammatory 
cytokines, such as IL-6, by antigen presenting cells. To date, IL-6 hasn’t been shown to 
be produced in mESCs (Guo, Graham-Evans et al. 2006).   
TNF-α is a cytokine produced by TLR-2/4 signaling, and is required for dendritic 
cell maturation and migration. (Kurt-Jones, Sandor et al. 2004; Adema, de Vries et al. 
2005). It is a major player in anti-tumor immunity and has been shown to reduce the 
activation of integrin αVβ3, an adhesion receptor that plays a key role in tumor 
angiogenesis, and causes a decrease in endothelial cell adhesion and survival (Ruegg, 
Yilmaz et al. 1998).    
The cytokines whose production are signaled via TLRs play a role in cell survival 
and replenishment of the innate immune system and we sought to determine if they play a 
role in the proliferation and survival of undifferentiated mES cells. ES cells are in a 
highly regulated environment and respond to various growth factors, chemokines, and 
cytokines differently. Studies have shown that bone morphogenic protein-4 (BMP-4), an 
anti neural factor in embryos in conjunction with LIF helps to maintain ES cells in a 
pluripotent state. Yet when ES cells are in BMP media alone, they differentiate into 
mesoderm and hematopoietic cells (Hilton, Hilton et al. 1994; Johansson and Wiles 1995; 
Ying, Stavridis et al. 2003). BMP interacts with serine threonine receptor heterodimers, 
while TLRs interact with MyD88 which activates serine threronine IRAK kinases IRAK1 
and IRAK4 (Hilton, Hilton et al. 1994; Ying, Stavridis et al. 2003). BMP has no direct 
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effect on the STAT-3 pathway nor does it inhibit the MAPK/ERK pathway, suggesting 
that it acts in parallel with LIF/STAT-3 (Hilton, Hilton et al. 1994).  
The cytokines produced by undifferentiated ES cells may be important in 
maintaining their stable environment and increase their survival and proliferation. When 
this niche is disrupted (i.e. when the ES cells are irradiated), there is an increase in levels 
of several cytokines whose production is induced upon TLR activation in other cell types. 
Therefore, we propose that these cytokines may play a role in ES cell survival because 
these cytokines may normally be used to maintain the hematopoietic stem cell niche 
(Hackney, Charbord et al. 2002; Zhang, Niu et al. 2003). The levels of these cytokines 
were at lower levels or not detected in normal mES cell conditioned media (Guo, 
Graham-Evans et al. 2006). The cytokines that were at higher levels under apoptotic 
conditions include IL-6 and TNFα. Production of the latter cytokines mentioned, are 
induced when either TLR-2 or TLR-4 are activated on other cell types such as MSC  
(Pevsner-Fischer, Morad et al. 2007).  
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AIMS 
 
AIM 1: Determine if murine Embryonic Stem (ES) cells express functional Toll Like 
Receptors (TLR), and if their ligands can induce or modulate murine ES cell 
proliferation/survival, self renewal and/or differentiation in the presence of Leukemia 
Inhibitory Factor (LIF). 
  
AIM 2: Clarify the roles of TLR ligands and their receptors on ES cell function under 
differentiating conditions in the absence of LIF. 
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MATERIALS AND METHODS 
 
Part I 
 
Do murine ES cells express Toll Like Receptors? 
 
Cell Cultures 
Wild-type ESC lines, E14, R1, CGR8 were cultured on gelatinized plates in Dulbecco’s 
modified Eagle’s medium (DMEM) with 15% ESC qualified fetal bovine serum (FBS) 
(Gibco-BRL, Grand Island, NY), 5.5x 10
-2
 mM β-mercaptoethanol (Gibco-BRL, Grand 
Island, NY) and 10
3
 U/mL of LIF; (Chemicon, Temecula, CA). Raw264.71, a mouse 
macrophage cell line, was purchased from ATCC (Manassas, VA) and cultured in 
DMEM (Gibco, Grands Island, NY) with 15% FBS. 
 
Primers 
RT-PCR primers were designed and optimized as previously reported (Derbigny, Hong et 
al. 2007) (Table 1). Primers were purchased from Invitrogen (Carlsbad, CA). 
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Table 1. Primers used for RT-PCR
Product Sense Primer Anti Sense Primer
Product
Size(bp)
TLR1 5'-GTGAATGCAGTTGGTGAAGAAC-3' 5'-GCTCATTGTGGGACAAATCCAA-3' 450
TLR2 5'-CTTGTTTCTGAGTGTAGGGGCT-3' 5'-CGAACCAGGAGGAAGATAAACT-3' 483
TLR3 5'-ACCCTTTCAAAAACCAGAAGAATC-3' 5'-GGACAGACGCTGTATATTGTTG-3' 521
TLR4 5'- TCAACCCCTTGAAGATCTTAAA-3' 5'-CAATTGGGTTCAAAGACATGTC-3' 459
TLR5 5'-CAGTATCAGCTGATGAGACATGAG-3' 5'-GACAGTACCGCAATAGGGATGG-3' 463
TLR6 5'- TACGGAGCCTTGATTTCCATGT-3' 5'-TGGACCTCTGGTGAGTTCTGAT-3' 485
TLR7 5'-AACCACATACCAAGCATCTCTC-3' 5'-AAATTAGGTGGCAAAGTGGTGG-3' 458
TLR8 5'-CAGAGTTGGATGTTAAGAGAGA-3' 5'-GTATATAACTGGTTGTCTTCCA-3' 459
TLR9 5'-GCCTGAGCCACACCAACATCCT-3' 5'-CCAGACCTTGGAACCAGGAAGA-3' 477
 
Adapted from (Derbigny, Hong et al. 2007) 
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RNA Extraction  
5 x 10
 5
 E14 mES cells were seeded in 60 mm culture dishes and grown to confluency. 
Total cellular RNA was extracted using the QIAGEN RNeasy Kit
TM
 according to 
manufacturer’s instructions (Qiagen Inc., Valencia, CA, USA).  RNA was stored in 
RNAse- free water at -80°C. 
 
DNase Treatment  
RNA samples were DNase treated using QIAGEN DNase free
TM
 according to 
manufacturer’s instructions (Qiagen Inc., Valencia, CA, USA). 
 
Reverse transcriptase-polymerase chain reaction  
Expression of TLRs 1 -9 and GAPDH were measured using a semi quantitative RT-PCR 
one-step AccessQuick 
TM 
RT-PCR system. (Promega, Madison, WI). The oligonucleotide  
primers  used for TLR-1 –TLR-9 and GAPDH have been reported (Derbigny, Hong et al. 
2007). Total RNA was isolated from the E14 mESC line and Raw 264.71 mouse 
macrophage cells using RNeasy minicolumns (QIAGEN, Valencia, CA). All RNA 
samples were treated with RNasefree DNase I (QIAGEN, Valencia, CA) to remove 
genomic-DNA contamination and were quantified by spectrophotometric analysis. RNA 
integrity was confirmed by agarose gel electrophoresis. Using 1µg of total RNA as the 
template for each reaction, RT-PCR was accomplished by using a polymerase kit (Access 
RT-PCR; Promega, Madison, WI). Cycling conditions were as follows: 1 min and 30 s of 
initial denaturation at 95°C, followed by eight cycles of 30 s at 95°C, 15 s at 60°C, and 
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30 s at 72°C. After the initial 8 cycles, the 30-s 72°C extension cycle was increased 3 s 
per cycle for 25 cycles. During the 40th cycle, the 72°C extension was 3 min to complete 
the RT-PCR. Reactions were also amplified in the absence of reverse transcriptase as 
negative controls. PCR products were electrophoresed on 1.5% agarose gels. Each DNA 
band was visualized by staining with ethidium bromide. Experiments were done in 
triplicate. 
 
Primary antibodies and TLR ligands 
Primary antibodies were: isotope-control PE rat IgG2a (eBioscience, San Diego, CA;  17-
4331), isotype-control APC rat IgG2b (eBioscience, San Diego, CA;12-4321), TLR2 
/CD282 anti-mouse clone 6C2 (eBioscience, San Diego, CA ;17-9021) and anti-mouse 
TLR-4/MD2 (eBioscience , San Diego, CA; 12-9924), p-IKKα/β (Cell Signaling, Denver, 
MA; 2697S), myeloid derived factor 88 (MyD88) (Abcam, Cambridge, MA; ab 2068), 
total IKKα/β (Santa Cruz, Santa Monica, CA; sc7607), NF-κB p65 (Upstate Cell 
Signaling Solutions, Temecula, CA; 0701049995), PARP (Cell Signaling, Denver, MA; 
9542), and blocking anti-TLR-2 antibody, T2.5 (Biolegend, San Diego, CA; 121802), 
and ERK1/2 (Cell Signaling, Denver, MA; 9102). TLR ligands included: TLR-2 agonist, 
Pam3Cys, and TLR-3 agonist, Poly I:C purchased from (Invitrogen, Carlsbad, CA). TLR4 
agonist, LPS from Salmonella was from Sigma Aldrich, St. Louis, MO. 
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Flow Cytometric Analysis for TLR-2 and TLR-4  
An aliquot of 1x 10
6
 cells was washed in PBS containing 1% BSA (PBS-1% BSA) three 
times. 100µl of staining buffer (PBS containing 1% BSA and .5% EDTA)  was added to 
the cell pellet along with 5µL of TLR-1-PE, TLR4-PE, or TLR-2-APC antibody for 1hr 
in the dark at 4°C. Cells were washed three times with wash buffer (PBS containing 1% 
BSA) and 300µL of wash buffer was added to cells and cells for analysis by flow 
cytometry. IgG2a was used as an isotype control for TLR1-PE, and TLR4-PE and IgG2B 
was used as an isotype control for TLR-2-APC 
 
Flow Cytometric Analysis for Oct-4, SSEA-1, SOX 2, and KLF-4 
Wild-type ESC lines E14, R1, and CGR8 were cultured with and without TLR-2, TLR-3, 
and TLR-4 agonists. Cells were collected after days 1, 2, 3, 4, and 5 for proliferation 
assay and after 30 minutes, 1 hr, and 4 hrs of TLR-agonist treatment. An aliquot of 1x 10
6
 
cells was washed in PBS containing 1% BSA (PBS-1% BSA) and incubated with anti-
mouse CD16/CD32 receptor monoclonal antibody at 1µg/100µL (Pharmigen, San Diego, 
CA) to block non-specific binding of immunoglobulin to mouse FcIII/II receptors, and 
cells were used for SSEA-1 antibody staining. Cells analyzed for SSEA-1 expression 
were incubated with a 1:20 dilution of monoclonal anti-SSEA-1 antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) for 1 hour at 4°C.   
             Cells were then washed and incubated with a 1:100 dilution of FITC: goat anti-
mouse IgM antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and analyzed. 
Remaining cells were fixed and permeabilized with Cytoperm/Cytofix (BD Biosciences, 
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San Jose, CA) and stained with a 1:100 dilution rabbit-mouse Oct-3/4 polyclonal 
antibody (Chemicon, Temecula, CA) and KLF-4 and Sox-2 antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA ) for 1hr at 4°C in the dark. Cells were washed 3 times 
with 1mL of 1x Perm/Wash Buffer, followed by staining with 1:100 dilution of FITC: 
goat anti-mouse IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Finally, cells 
were washed 3 times with 1x Perm/Wash Buffer and resuspended in 300µL of 1x Perm 
Wash Buffer for FACScan analysis (Becton Dickinson, Sunnyvale, CA). 
 
Western Blot p-IKK, Total IKK, and MyD88 
Cells were lysed with 100µL of MPER (Pierce, Rockland, IL) with proteinase and 
phosphatase inhibitors added (40µL of proteinase and phosphatase inhibitors added to 
4mL of MPER).  The 1.5mL centrifuge tube was vortexed to resuspend the pellet into 
solution. Total protein in supernatant was collected. 
After protein was collected, we determined protein concentration using BCA 
analysis reagents (Pierce, Rockland, IL). Standards were made using 200µL of BCA 
reagents and 20µL of each standard (125µg/mL-2000µg/mL). Samples were plated at a 
1:10 dilution. All sample and standards were performed in triplicate. The plate was 
incubated at room temperature for 2 hours and analyzed using a spectrophotometer with a 
plate reader at 540nm. 
  After protein concentration was determined, 40µg/40µL of each protein sample 
was used to perform Western blotting analysis of E14 cells. Protein was electrophoresed 
on a 4-12% gel (Invitrogen, Carlsbad, CA) in the X Cell II Sure Lock Apparatus 
  
27 
(Invitrogen, Carlsbad, CA) at 120V for 1 hr. Next the gel was transferred to the PVDF 
membrane (Millipore, Temecula, CA) in the Cell II Blot Module (Invitrogen, Carlsbad, 
CA) in the X cell II Sure Lock apparatus (Invitrogen, Carlsbad, CA) at 25 V at 4°C for 
2hrs. The MyD88 anti-rabbit (Chemicon, Temecula, CA), p-IKK anti -rabbit, Total- IKK, 
anti-rabbit, and β-actin anti-mouse (Santa Cruz Biotechnology, Santa Cruz, CA) 
antibodies were used. β-actin anti-mouse antibody was used as a loading control. 
 
Enzyme Linked Immunosorbent Assay (ELISA) for Protein 
Cytokine release was assessed by enzyme linked immunosorbent assay (ELISA) with 
5x10
5
 ESCs seeded in 24 well plates. Twenty-four hours later, the media was replaced 
with DMEM with or without the ligands for TLR-2 or TLR-4 respectively. IL-6, TNF-α, 
and IFN-β protein amounts were determined by ELISA (Ready-SET-G0! ELISA kit, 
(eBioscience San Diego, CA) according to manufacturer’s instruction. Standard curves 
were established using mouse recombinant IL-6, TNF-α and IFN-β growth factors 
respectively. The assay detection limit was 4 pg/mL protein.   
 
IL-6, TNF-α and IFN-γ mRNA and protein expression 
Total RNA was isolated by TRIZOL preparation followed by phenol chloroform/isoamyl 
alcohol extraction and ethanol precipitation. Changes in IL-6, TNF-α, and IFN-γ RNA 
levels in mES cells were analyzed by quantitative real time PCR polymerase chain 
reaction. Primers used for this assay were obtained from the Dent laboratory and are 
shown in Table 2. Relative changes in IL-6, TNF-α, and IFN-γ were determined using the 
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2
-ΔΔCt
 method. Data are expressed as fold change. To test our q-RT-PCR primers we 
analyzed cytokine expression in Raw264.71 mouse macrophage-like cells stimulated with 
TLR-2 and TLR-4 ligand. 
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Table 2. Primers for qRT-PCR
Product Sense Anti-Sense
TNF-α 5'-CACAAGATGCTGGGACAGTGA-3' 5'-TCCTTGATGGTGTGCATGA-3'
IFN-γ 5'-TCAAGTGGCATAGATGTGGAAGAA-3' 5'-TGGCTCTGCAGGATTTTCATG-3'
IL-6 5'-CCAGAAACCGCTATGAAGTTCCT-3' 5'-CACCAGCATCAGTCCCACGA-3'
β-tubulin 5'-CTGGGAGGTGATAAGCGATGA-3' 5'-CGCTGTCACCGTGGTAGGT-3'
Obtained from Dent laboratory
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Proliferation Assay  
We cultured E14 ES cells in the presence of LIF and the TLR-2 activator Pam3Cys in our 
experiments for cell suspension proliferation assays. ES cells under undifferentiated 
conditions without Pam3Cys stimulation served as a control. One hundred thousand E14 
mESCs were stimulated with 0.1µg/mL, 0.5µg/mL, and 1.0µg/mL of Pam3Cys in 5 mL 
of undifferentiated media. Incomplete Media includes DMEM for undifferentiated ES 
cells (Hyclone, Waltham, MA), 15% FBS, 1% Penicillin/Streptomycin (Gibco, Grand 
Island, NY), 1% Pyruvate (Gibco, Grand Island, NY), 1% MEM Essential Vitamins 
(Gibco, Grand Island, NY), and 1% L-Glutamine (Gibco, Grand Island, NY). Complete 
Media was made with 50mL of incomplete media plus LIF at [1:10000] and β2-
mercapthoethanol (2ME) at [1:1000] which were added fresh. Next the ES cells were 
incubated in a 5% CO2 37°C incubator for 5 days.  
To harvest cells for counting each day cells were washed with 3mL of PBS, 
trypsinized with 1mL of trypsin-EDTA (Gibco, Grand Island, NY), and placed in the 
incubator for 5 minutes to remove cells from the bottom of plates. ES cells were washed 
with 5mL of incomplete media and spun down for 5 minutes at 12,000 rpm. Supernatant 
was removed and 1mL of incomplete media was added to the cells. Next 50µL of the 
cells were stained with 50µl of Trypan Blue (Gibco, Grand Island, NY) and 10µL of the 
cells was counted on the hemacytometer. This was done for samples harvested each day 
for the cells treated with or without Pam3Cys ligand. 
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Survival Assay for ESCs in the Presence of LIF 
 
ESC growth depends on serum. After withdrawal of serum from plates <25% confluency, 
95% of ESCs die within 96 hours. To determine the effects of TLR-2 ligand, Pam3Cys on 
ESC survival, studies evaluated control medium, 200ng/mL SDF-1/CXCL12, 0.1μg/mL, 
1.0μg/mL, and 10μg/mL of Pam3Cys, and 0.1μg/mL, 1.0μg/mL, and 10μg/mL of LPS. 
Reagents were added at the beginning of the experiments, and mES cell cultures were 
initiated without serum in 1% methylcellulose-based DMEM (5.5x 10
-2
mM 2-ME and 
10
3
U/mL LIF) (Chemicon, Temecula, CA) at 2000 cells/mL. Serum was added at 0, 24, 
48, or 96 hours to each group and colonies scored 7 days after addition of serum. The 
undifferentiated status of the cells was checked by staining of the cells with anti-mouse 
Oct-4, Sox-2, KLF, and SSEA-1 antibody. 
 
Apoptosis Assay 
To analyze mESC’s undergoing apoptosis, cell cultures were subjected to serum 
withdrawal in the presence of LIF. Reagents were added at the beginning of cultures as 
followed: Control medium, TLR-2 ligand, Pam3Cys (10µg/mL), TLR-4 ligand, LPS 
(10µg/mL), and SDF-1/CXL12 (200ng/mL). Cells were collected at days 1, 2, 3, and 4 
after serum withdrawal and were stained with Annexin V (BD Biosciences, San Jose, 
CA). After withdrawal of serum for 4 days, mESCs were stained with undifferentiated 
markers Oct4, KLF4, SSEA1, and Sox2, respectively to determine if the cells remained 
undifferentiated.   
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Part II 
 
Day 4 and Day 6 EBs in Suspension 
We plated 1000 E14 mES cells/mL with or without 10µg/mL or 20μg/mL of Pam3Cys in 
IMDM media in the absence of LIF and mixed cells well in a 50mL conical tube before 
they were plated into a 35mm tissue culture plate. EB’s are formed from ES cells in the 
absence of LIF. We plated cells in the absence of LIF for 4 and 6 days. 
 
Flow Cytometry of Day 4 and Day 6 EBs 
 EB’s were accessed by flow cytometry for TLR-2 and TLR-4 and for non-differentiation 
markers like SSEA-1, Oct-4, Sox-2, and KLF-4 to determine if TLR-2 ligand will prevent 
the ES cells from differentiating to EB’s, therefore we only checked undifferentiated 
markers and not for increases in lineage markers or cell types. 
 
Western Blot of Oct-4, phosphorylated-ERK and Total ERK  
We performed Western blot analysis to determine if the TLR-2 ligand in the absence of 
LIF increased differentiation or helped to maintain stemness of ES cells, by looking at the 
expression of Oct-4 in the EBs treated with increasing doses of TLR-2 ligand as 
compared to EB’s not treated with ligand, and its control, mES cells cultured in the 
presence of LIF. Cells were lysed with 100µL of MPER (Pierce, Rockland, IL) with 
proteinase and phoshotase inhibitors added (40µL of proteinase and phosphotase 
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inhibitors added to 4mL of MPER). The 1.5mL centrifuge tube was vortexed to 
resusspend pellet into solution and spun at 4°C for 10 minutes.  
After protein was collected, we detected the protein concentration using BCA 
analysis reagents (Pierce, Rockland, IL). Standards were made using 200µL of BCA 
reagents and 20µL of each standard (125µg/mL-2000µg/mL), and samples were plated at 
1:10 dilution. All samples and standards were done in triplicate. The plate was incubated 
at room temperature for 2 hours and analyzed using a spectrophotometer with a plate 
reader at 540nm. 
  After protein concentration was determined, 40µg/40µL of each protein sample 
was used to perform Western blotting analysis of E14 Day 4 and Day 6 EBs. Protein was 
electrophoresed on a 4-12% gel (Invitrogen, Carlsbad, CA) in the X Cell II Sure Lock 
Apparatus (Invitrogen, Carlsbad, CA) at 120 V for 1 hr. Next the gel was transferred to 
the PVDF membrane (Millipore, Temecula, CA) in the Cell II Blot Module (Invitrogen, 
Carlsbad, CA) in the X cell II Sure Lock apparatus (Invitrogen, Carlsbad, CA) at 25 V at 
4°C for 2hrs.  The Oct-3/4 (Chemicon, Temecula, CA), p-ERK anti -rabbit, Total ERK 
anti-rabbit, and β-actin (Santa Cruz Biotechnologies, Santa Cruz, CA) anti-mouse 
antibody was used to determine if the undifferentiated ES cells marker was expressed in 
differentiating conditions in the presence of TLR-2 ligand. β-actin anti-mouse antibody 
was used as a loading control. 
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RESULTS 
 
Part I  
 
mES Cells effects in the presence of LIF 
 
TLR2 is expressed at the message level and on the surface of  mES cells 
               Previous reports have shown that TLRs when activated on HSCs can cause 
HSCs to differentiate into B cells and dendritic cells thus helping in the replenishment of 
the immune system (Nagai, Garrett et al. 2006). Mesenchymal Stem Cells (MSCs) 
express functional TLRs and TLRs play a role in bone repair, proliferation of MSCs and 
prevent MSC differentiation into chondrocytes, adipocytes and osteoclasts (Fischer, et.al 
2008). Little is known about TLRs and their role in mES cells, therefore we first 
determined if TLRs are expressed at the messenger RNA level using primers for TLRs 1-
9 (Table 1). We found that mRNA for TLRs 1, 2, 3, 5, and 6 were expressed but not for 
4, 7, 8, and 9 (Figure 5 A). Raw264.71, a mouse macrophage like cell line was used as a 
positive control expressing TLR-1-9 respectively (Figure 5 B and Table 2). There are 
antibodies available that detect TLR-2 and TLR-4 protein on the cell surface. Next, we 
determined if TLR-2 was expressed on the surface of mES cells and since mRNA for 
TLR4 was not expressed, we looked for protein expression of TLR-4, as a negative 
control. We found that TLR-2, but not TLR-4 was expressed on the surface of E14 mES 
cells (Figure 6) confirming the data shown at the gene level. Raw264.71 was used as a 
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positive control and expressed TLR-2 and TLR-4 on its surface. We also checked R1 and 
CGR8 mES cells for TLR-2 and TLR-4 expression. We show that these cell lines express 
TLR-2 but not TLR-4 (Figure 7 and 8). These data show that TLR-2 is expressed on three 
mES cells, so we then focused on determining if TLR-2 was functional on E14 mES 
cells. 
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Figure 5. A.) Murine embryonic stem cells express mRNA for TLRs 1, 2, 3, 5 and 6 
obtained from wildtype, E14 C57/B6 cell line. mES cells were subjected to RT-PCR with 
primers specific for TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, and 
TLR-9. PCR products were separated by 2% agarose gel electrophoresis and visualized 
with ethidium bromide, * marks appropriate size of RT-PCR products, -RT, control 
samples without reverse transcriptase were a negative control for all primers (not shown), 
+, GAPDH served as a positive control. B.) Raw264.71 was used as a positive control for 
all primers. These results are representative of the same findings in six separate 
experiments. 
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Figure 5 
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Table 3. TLR1-9 mRNA expression in cell lines
Cell line TLR1 TLR2 TLR3 TLR4 TLR5 TLR6 TLR7 TLR8 TLR9
E14 + + + - + + - - -
Raw264.71 + + + + + + + + +
TLR mRNA levels were determined by RT-PCR using mouse specific primers.
Levels are noted as +, strong band, - band not detected.
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Figure 6. Expression of TLR-2, and TLR-4 was analyzed on the surface of E14 mES 
cells. A. TLR-2 was expressed on mES cells compared to IgG2a isotype control, B.TLR-
4 was not expressed on the surface of mES cells compared to isotype control IgG2b, 
Raw264.71 mouse macrophage cell line was used as a positive control to confirm that the 
antibodies worked properly C.TLR-2-APC, and D.TLR-4-PE. TLR-2-APC and TLR-4-
PE protein levels were analyzed by flow cytometry. IgG2a-APC and IgG2b-PE were 
used as the respective isotype controls for both cell lines in each separate experiment. 
These results are representatives of similar finding in 4 experiments mcf=mean cell 
fluorescence, a measure of the expression levels of protein on the cell surface. 
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Figure 7. Expression of TLR-2, and TLR-4 was analyzed on the surface of CGR8 mES 
cells. A. TLR-2 was expressed on mES cells compared to IgG2a isotype control, B.TLR-
4 was not expressed on the surface of mES cells compared to isotype control IgG2b, 
Raw264.71 mouse macrophage cell line was used as a positive control to confirm that the 
antibodies worked properly C.TLR-2-APC, and D.TLR-4-PE. TLR2-APC and TLR-4-PE 
protein levels were analyzed by flow cytometry. IgG2a-APC and IgG2b-PE were used as 
the respective isotype controls for both cell lines in each separate experiment. These 
results are representatives of similar findings in 4 experiments mcf=mean cell 
fluorescence, a measure of the expression levels of protein on the cell surface. 
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Figure 8. Expression of TLR-2, and TLR-4 was analyzed on the surface of R1 mES cells. 
A. TLR-2 was expressed on mES cells compared to IgG2a isotype control, B.TLR-4 was 
not expressed on the surface of mES cells compared to isotype control IgG2b, 
Raw264.71 mouse macrophage cell line was used as a positive control to confirm that the 
antibodies worked properly C.TLR-2-APC, and D.TLR-4-PE. TLR-2-APC and TLR-4-
PE protein levels were analyzed by flow cytometry. IgG2a-APC and IgG2b-PE were 
used as the respective isotype controls for both cell lines in each separate experiment.   
These results are representatives of similar findings in 4 experiments mcf=mean cell 
fluorescence, a measure of the expression levels of protein on the cell surface. 
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Treatment of mES cells with TLR-2 ligand Pam3Cys increases NF-κB nuclear 
translocation 
mES cells were plated in the presence and absence of Pam3Cys, a TLR-2 ligand, for 15 
minutes to 1 hour in the presence of LIF. The concentration of TLR ligands were based 
on prior studies . Cells that were treated with 10μg/mL of Pam3Cys, showed an increase 
in NF-κB nuclear expression compared to cells that were not treated. Cells were also 
treated with 10 μg/mL of bacterial lipopolysacchride (LPS), a TLR-4 ligand, but no 
enhancement in translocation was detected with LPS (Figure 9). We also checked for the 
expression of MyD88 and p-IKK in the E14 mESCs (Figure 10 and 11). We show that 
the E14 mESCs express MyD88, and after 15 minutes exposure to TLR-2 ligand 
Pam3Cys or 30 minutes with Poly I:C, a ligand for TLR-3, the mES cells show an 
increase in phosphorylation of p-IKK demonstrating that TLR-2 and TLR-3 are 
functional likely by the MyD88/IKK pathway in the E14 mES cells (Figures 10 and 11).  
 
TLR-2 Ligand Pam3Cys enhances E14 mES cell Proliferation   
To determine if TLR-2 plays a role in mES cell proliferation, mES cells were treated with 
varying doses of the TLR-2 ligand, Pam3Cys in presence of LIF.  mES cells manifested a 
significant 2 fold increase in total cell number by day 3 at each dosage of Pam3Cys 
(Figure 12 A). This increase was also noted at days 4 and 5 (Figure 12 A and B). In order 
to determine if the Pam3Cys effects were mediated through TLR-2, we performed 
experiments in the presence and absence of a blocking antibody for TLR-2 (T2.5). The 
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antibody blocked enhanced proliferation on day 3 induced by Pam3Cys (Figure 12 C and 
D).   
 
 Cytokine and chemokine expression levels upon stimulation with TLR-2 ligand 
mESCs were treated with Pam3Cys a ligand for TLR-2, Poly I: C, a ligand for TLR-3 and 
LPS, a ligand for TLR-4 in a 96 well plate for 18 hours. ELISA for IL-6, TNF-α and IFN- 
β were performed to determine if there would be an increase in cytokine release upon 
TLR challenge. mES cells showed no release of detectable IL-6, TNF-α, or IFN-β  
proteins (Figure 13).  
                 In contrast, we did detect TLR-2-ligand enhancement of the mRNA expression 
for IL-6 (Figure 14 A), TNF-α (Figure 14 B.) and IFN-γ (Figure 14 C). Previous reports 
have shown that TNF-α, and IL-6 were not detected in normal media of the mES cell but 
were detected in mES cells that have undergone apoptosis (Guo, Graham-Evans et al. 
2006). Next we treated the E14 mES cells with the ligands for TLR-2, TLR-3, and TLR-4 
and we measured release of a number of cytokines and chemokines noted in Table 3. We 
did not detect enhanced release of cytokines or chemokines see e.g. Table 4. Samples 
were assessed for cytokine and chemokine production, and sensitivity for each are 
denoted at charlesriver.com. (Charles River Molecular Diagnostic Laboratory, 
Wilmington, MA). 100 µL of media from E14 mESCs in the presence and absence of 
TLR-2 ligands were sent Charles River Molecular Diagnostics Laboratory to measure 58 
different cytokines and chemokines by ELISA (Table 3).  
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Next we wanted to determine if downstream targets to NF-κB would become activated. 
We looked for BCL-2 expression after 12 and 24 hours of TLR-2 stimulation (Figure 14 
D). We saw an increase in BCL-2 expression after 24 hours in the presence of TLR-2 
ligand, showing that NF-κB was functional in mES cells after 24 hours of ligand 
treatment. Expression of cytokines by the E14 mES cells showed minimal expression 
when compared to Raw264.71 macrophage- like cell line, the positive control after 12 
hours (Figure 14 E, F, and G). 
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Figure 9. Pam3Cys enhances NF-κB nuclear translocation in mES cells. 1x 10
6
 mESCs 
were plated in DMEM media in the presence of LIF. Once the cells reached confluence, 
10 μg/mL Pam3Cys or 1µg/mL of LPS was added directly into the media. mES cells were 
harvested at 30 minutes or 1 hour and nuclear and cytoplasmic proteins were extracted. 
The cytoplasmic (A and C) and the nuclear (B and D) were quantified, run on SDS-Page 
gel and blotted with an anti NF-κB p65, PARP or total ERK1/2 antibodies, The 
autoradiographs were quantified by densitometry and shown the average results of 3 
separate experiments (C and D).    
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Figure 10. MyD88 is constituitvely expressed in mESCs with and without TLR-2 ligand 
activation for 15 minutes to 4 hours. β-actin was used as a loading control. Results shown 
are for one of two experiments with similar results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
51 
          
                         
             
             
 
 
Figure 10 
 
 
 
 
 
 
 
                 
  
52 
Figure 11. TLR-2- activation in mESC cause phosphorylation of IKK-α/β at 15 and 30 
minutes with the ligand for TLR-2 and TLR-3. Total IKK and β-actin was used as a 
loading control for experiments. Shown are the results of 1 of two reproducible 
experiments.  
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Figure 12. Pam3Cys enhances ES cell numbers on Day 3, 4, and 5 in the presence of LIF. 
A. ES cells were treated with Pam3Cys at varying doses for up to 96 hours. Significant 
changes are noted when compared to control for each day. B. Total cell number for each 
day with and without TLR-2 stimulation. C. Day 2 and Day 3 proliferation in the 
presence and absence of T.25 a blocking antibody for TLR-2 receptor with and without 
ligand. D. Day 3 proliferation assay in the presence and absence of TLR-2 ligand with 
and without blocking TLR-2 antibody (T.25). Results shown are the average of 3 
experiments with each experiments performed in triplicate. p value < .05. 
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Figure 13. mESCs do not secrete various cytokines and chemokines following 
stimulation with TLR ligands, as assessed by ELISA. mES cells cultures were treated 
with various TLR ligands: 75μg/mL Poly (I:C), 10μg/mL LPS, or 10μg/mL Pam3Cys, as 
noted, for 24 hours prior to harvesting the conditioned medium. While cytokine release in 
response to TLR ligands was detected in media conditioned by Raw264.71 cells, it was 
not detected (ND) in media conditioned by mES cell line E14. These are results each of 
one experiment performed in triplicate.  
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B. TNF-α 
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C. IL-6 
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Figure 14. qRT-PCR for A. IL-6 B. TNF-α, and C. INF-γ at 12 and 24 hrs after TLR-2 
and TLR-4 ligand stimulation on E14 mESCs. D. BCL-2 protein expression after TLR-2 
activation for 24 hours. E. IL-6, F. TNF-α, and G. INF-γ at 12 hours after TLR-2 and 
TLR-4 ligand stimulation on Raw264.71 mouse macrophage like cells. These are results 
of two experiments. Each performed in triplicate.  
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Table 4. Other Cytokines, Chemokines, and Growth Factors Assessed by ELISA 
Apolipoprotein A1 (Apo A1) Macrophage-colony stimulating factor (M-CSF)
C-Reactive Protein (CRP) Macrophage derived cytokine (MDC)
CD40 Macrophage inflammatory protein 1 α (MIP-1alpha)
CD40 ligand Macrophage inflammatory protein 1 β (MIP-1 beta)
Endothelin -1 Macrophage inflammatory protein 1 γ (MIP-1 gamma)
Eoxtaxin (MIP-2)
Epidermal Growth Factor Macrophage inflammatory protein 3 β (MIP-3 beta)
Factor VII Matrix metalloproteinase-9 (MMP 9)
Fibrinogen Monocyte chemoattractant protein -1(MCP-1)
Fibroblast growth factor basic (FGF-basic) Monocyte chemoattractant protein -3(MCP-3)
Fibroblast growth factor -9 (FGF-9) Monocyte chemoattractant protein- 5(MCP-5)
Granulocyte chemotactic protein 2 (GCP-2) Myeloperoxidase
Granulocyte macrophage-colony stimulating factor 
(GM-CSF) Myoglobin
Glutathione S-transferase α (GST-alpha) Oncostatin M (OSM)
Haptoglobin
Regulation upon activation, normal T-cell expressed and 
secreted (RANTES)
Immunoglobulin A (IgA) Serum Amyloid P
Inducible Protein-10 (IP-10) Serum glutamic-oxaloacetic transaminase (SGOT)
Insulin Stem Cell Factorn (SCF)
Interferon-gamma (IFN-γ) Thrombopoietin (TPO)
IL-1α (interleukin -1 alpha) Tissue inhibitor of metalloproteinase type – 1 (TIMP1)
IL-1β (interleukin-1 beta) Tissue Factor
IL-2 (interleukin-2) Tumor Necrosis Factor-alpha (TNF-α)
IL-3 (interleukin-3) vascular cell adhesion molecule -1 (VCAM-1)
IL-4 (interleukin-4) Vascular endothelial cell growth factor (VEGF)
IL-5 (interleukin 5) Von Willebrand Factor (vWF)
IL-6 (interleukin 6) Leptin
IL-7 (interleukin 7) Leukemia inhibitory factor (LIF)
IL-10 (interleukin 10) Lymphotactin
IL-11(interleukin 11)
IL-12p70 ( interleukin- 12p70)
IL-17 (interleukin 17)
Melanoma growth stimulatory activity protein 
(KC/GRO alpha)
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Table 5. Effects of Toll Like Receptor ligands on the capacity of E14 cells to release 
protein
Increased protein 
release 
TLR2 
challenge
TLR3 
challenge
TLR4  
challenge
Conditioned
Media
after ligand 
stimulation (pg/mL) (pg/mL) (pg/mL) (pg/mL)
CRP 2433+513 2300+265
EGF 5.1+ 0.30 5.1+ 2 4.7+0.81
Fibronogen 12000+ 1000 13000+1000 10500+1323
IL-17 2.0+0.1 1.5+0.25
IFN-β 3+1.1 2+0.4
Haptoglobin
223333+305
50 230000+ 4826 21667+57258
GM-CSF 0.23+0.06 0.24+0.06 0.19+0
GCP-2 1.8+ 0.83 1.7+0.4
IL-4 7.1+1.15 5.8+0
IP-10 15+8 13+ 8
MCP-1 4+0.8 2.4+0.8
MCP-3 6+0.6 4.2+0.2
KC/GRO-α 9.1+5 2.4+0.7
(SAP) 8933+3153 8867+2650
IL-6 0.7+0.6 0.06+0.5
IL-12p70 16+8 12+7
IL-17 2+ 0.1 1.5+ 0.25
Lymphotactin 4.13+0.5 3.93+1.5
MIP-1 alpha 81+12 88+0 81+12 76+29
SGOT 8000+13856 12333+21362 20000+3606 nd
MIP-2 2.4+0.1 2.2+0.1 1.9+0.5
VEGF 673+250 591+279 578+500
FGF-9 163+23 130+52 118+56
IgA 28333+90738
256667+15044
3
IL-1 alpha 13+2 12.6+2.5
 
                   Table shows average level of cytokine expression +/- SD (pg/mL). 
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mESCs maintain an un-differentiated state after TLR-2 activation in the presence of 
LIF 
mESCs were treated with TLR-2 and TLR-4 ligand for up to 3 days. We observed that 
TLR-2 and TLR-4 ligands did not change the expression of undifferentiated markers Oct-
4, SSEA-1, KLF, and Sox-2, when compared to cells that were not treated with TLR 
ligands (Figures 15-18). Thus, TLR2 ligand- TLR2 interactions in the presence of LIF do 
not appear to trigger differentiation of mES cells (Figures 15-18), although more 
rigourous methods of assessor the non-differentiated of ES cells, e.g. invivo/teratoma 
formation will he needed to condusively, determine this.    
 
Pam3Cys enhances and LPS decreases mES cell survival upon delayed addition of 
serum 
mES cells were plated in the presence of LIF, but with delayed addition of serum for 0, 1, 
2 and 4 days and in the absence or presence of Pam3Cys, the ligand for TLR-2, LPS, or 
SDF-1. SDF-1 was used as a positive control because our lab has shown that SDF-1 
caused an increase in survival of mESCs in the presence of LIF with delayed addition of 
serum (Guo, Graham-Evans et al. 2006). As shown in Figure 19A, SDF-1 showed a 
significant increase in cell survival compared to cells that were not treated and also 
compared to cells treated for each day with 0.1μg/mL, 1.0 μg/mL, and 10 μg/mL of TLR-
2 ligand. mES cells treated with the ligand for TLR-2 showed a dose-dependent increase 
in survival when compared to cells that were not treated for each day. Pam3Cys resulted 
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in decreased apoptosis (Figure 19 B) interestingly, LPS triggered a decrease in survival 
(Figure 19 A) and an increase in apoptosis (Figure 19 B). 
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Figure 15. Surface expression of stem cell marker SSEA-1 after TLR-2 and TLR-4 ligand 
stimulation in wild-type E14 mESCs in the presence of LIF. SSEA-1 protein levels were 
analyzed by flow analysis. These are one of three experiments showing the same 
expression levels.  
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Figure 16. Intracellular expression of stem cell marker Oct 3/4 after TLR-2 and TLR-4 
ligand stimulation in wild-type E14 mESCs in the presence of LIF. Oct 3/4 protein levels 
were analyzed by flow analysis. These are one of three experiments showing the same 
expression levels.  
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Figure 17.  Intracellular expression of stem cell marker KLF-4 after TLR-2 and TLR-4 
ligand stimulation in wild-type E14 mESCs in the presence of LIF. KLF-4 protein levels 
were analyzed by flow analysis. These are one of three experiments showing the same 
expression levels.  
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Figure 18. Intracellular expression of stem cell marker Sox 2 after TLR-2 and TLR-4 
ligand stimulation for wild-type E14 mESCs in the presence of LIF. SOX-2 protein levels 
were analyzed by flow analysis. These are one of three experiments showing the same 
expression levels.  
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Figure 19. Influence of TLR-2 on survival of mES cell colony formation subjected to 
delayed addition of serum (A), and of apoptosis of mES cells in suspension culture as 
assessed by flow cytometry. The percent Annexin V-positive cells were compared to the 
controls of that specific day *p< 0.05. (B). mES cells were cultured without serum, and 
serum added at day 0, 1, 2, and 4 after the start of culture. Colonies formed by ESCs were 
counted 7 days after addition of serum. Results shown are the average of three 
experiments, each assessed in triplicate. Experimental points were compared with the 
time 0 of the control group: (*) p< 0.05.  
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RESULTS 
 
Part II 
 
mES Cell Differentiation 
 
TLR-2 and TLR-4 are expressed in Embryoid Bodies (EBs) 
TLR-2 and TLR-4 protein expression was examined by flow analysis after removal of 
LIF. While we detected expression of TLR-2 and TLR-4 expression on the surface of 
mES cells after withdrawal of LIF, Pam3Cys did not influence TLR-2 expression (Figure 
20) and had only minimal effects on TLR-4 expression (Figure 21). 
 
In the absence of LIF, TLR2 activation caused an increase in expression of Oct-4 
and Sox-2 but not KLF-4 and SSEA-1 expression. 
We determined if Day 4 and Day 6 EBs derived from mESCs in the absence of LIF but in 
the presence of TLR-2 ligand at 10 μg/mL expressed non-differentiated markers Oct-4, 
Sox-2, KLF-4, and SSEA-1. As shown in Figures 22-25 respectively, mESCs in the 
absence of LIF, do not express Sox-2, SSEA-1, KLF-4, and Oct-4. In the absence of LIF 
and the presence Pam3Cys, there was a modest increase in expression of Sox 2 in Day 6 
EBs (Figure 22), no effect on expression of cell surface marker SSEA-1 on Day 4 or Day 
6 EBs (Figure 23), essentially no effect on expression of KLF in Day 4 or Day 6 EBs 
(Figure 24), and only a very modest increase in Oct 4 expression in day 6 EBs with 20 
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μg/mL Pam3Cys (Figure 25). Thus from the flow data, there is little evidence other than 
for Sox-2 (Figure 22) and Oct-4 (Figure 25) expression that Pam3Cys has effects on 
modifying differentiation of mES cells after removal of LIF. 
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Figure 20. Pam3Cys does not modify expression of TLR-2 after removal of LIF. Flow 
Cytometry results are shown for Day 6 EBs. These are one of three experiments showing 
the same expression levels.  
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Figure 21. Pam3Cys has minimal to no effects on expression of TLR-4 after removal of 
LIF. Flow Cytometry results are shown for day 4 and 6 EBs. These are one of three 
experiments showing the same expression levels.  
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Figure 22. Flow analysis of Sox2 expression for Day 4 and Day 6 EBs in the absence of 
LIF but in the presence of Pam3Cys for undifferentiated markers Sox 2. These are one of 
three experiments showing the same expression levels.  
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Figure 23. Flow analysis of SSEA-1 Expression for Day 4 and Day 6 EBs in the absence 
of LIF but in the presence Pam3Cys. These are one of three experiments showing the 
same expression levels.  
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Figure 24. Flow analysis of KLF4 expression for Day 4 and Day 6 EBs in the absence of 
LIF but in the presence of Pam3Cys. These are one of three experiments showing the 
same expression levels.  
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Figure 25. Flow analysis of Oct4 expression for Day 4 and Day 6 EBs in the absence of 
LIF but in the presence of Pam3Cys. These are one of three experiments showing the 
same expression levels.  
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Oct-4 levels, as assessed by Western blot, were maintained and a decrease in p-ERK 
in Day 6 EBs compared to EBs not treated with TLR-2 ligand 
mES cells were plated in the absence of LIF for 6 days, but in the presence of Pam3Cys. 
As shown in Figure 26, Oct-4 and p-MEK were assessed by western blot analysis. Oct-4 
was highly expressed in R1 cells in the presence of LIF. This was used as a positive 
control compared to cells cultured in the absence of LIF for 6 days. In contrast to the flow 
data showing little to no expression of undifferentiated cell marker Oct-4, in the presence 
of Pam3Cys and absence of LIF we saw an increase in Oct-4 protein expression by 
Western blot analysis when compared to cells that were not treated with Pam3Cys (Figure 
26 A). Next, we checked for p-ERK expression in these cells (Figure 26 B). Removal of 
LIF resulted in enhanced expression of phosphorylated ERK, but this expression level 
was greatly decreased in the presence of Pam3Cys. β-actin and total-ERK were used as 
loading controls (Figure 26 C and D). 
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Figure 26.  mES cell line R1 treated with Pam3Cys, in the absence of LIF show lessened 
down regulation of Oct 4 expression but decreased expression of phosphorylated ERK 
(42kb) compared to cells in the absence of Pam3Cys. (A) Oct-4 (B) ERK 
phosphorylation.  mES cells were grown to confluency and induced to differentiate by the 
removal of LIF. (C) Total ERK and (D) β-actin antibody to confirm equal loading. 
Representative data from two independent experiments are shown. These are one of three 
experiments showing the same expression levels.  
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DISCUSSION 
 
Experiments in the presence of LIF 
TLRs are critical components of the adaptive immune response (Takeuchi, Hoshino et al. 
1999; Underhill, Ozinsky et al. 1999; Hoebe, Du et al. 2003; Honda, Murao et al. 2003; 
Lund, Sato et al. 2003; Diebold, Kaisho et al. 2004; Heil, Hemmi et al. 2004; Krieg, Efler 
et al. 2004; Lebon, Adler et al. 2004). These receptors are expressed on hematopoietic 
stem and progenitor cells (Nagai, Garrett et al. 2006), as well as other pluripotent cell 
types (Rolls, Shechter et al. 2007) including mesenchymal stem/stromal cells (Pevsner-
Fischer, Morad et al. 2007) and are selectively expressed on the mES cell line, D3 (Lee, 
Hong et al. 2009). While it is not entirely clear why mES cell lines would express TLRs, 
mES cell lines have been shown to express certain cytokine receptors, as well as produce 
cytokines that act on mES cell lines as well as on hematopoietic progenitor cells (Guo, 
Hangoc et al. 2005; Guo, Graham-Evans et al. 2006). Since our original studies on mES 
cell lines (Guo, Hangoc et al. 2005; Guo, Graham-Evans et al. 2006), we have been 
interested in a potential role for TLRs and their ligands in mESC line function. Our 
present study addresses our experiments on the expression of TLRs in the E14, CGR8, 
and R1 mES cells and the functional activities of Pam3Cys, a ligand for TLR-2, and to a 
lesser extent, the activity of LPS on the E14 mES cell line. These studies significantly 
extend those of others (Lee, Hong et al. 2009) with regards to TLR expression in mES 
cell lines, and not unexpectedly point up some subtle differences in expression of TLRs 
in different mES cell lines.  
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              We found that the E14 mES cell line growing in the presence of LIF expresses 
mRNA (as assessed by semi-quantitative RT-PCR) for TLRs 1, 2, 3, 5, and 6, but not 
TLRs 4, 7, 8, or 9. This profile of TLR expression differs from the D3 mES cell line by 
others (Lee, Hong et al. 2009), where RT-PCR analysis showed mRNA for TLRs 2-6, but 
not for TLR1 or 7-9, thus distinguishing differential expression of mRNA for TLR-1 and 
4 between the D3 and our E14 cell line.  Interestingly, we do not observe expression of 
cell surface protein for TLR4 on the E14, CGR8, and R1 mES cell lines, and we did not 
detect mRNA expression for TLR4 on the E14 mES cell line. These differences may be 
due to the cell line itself, or perhaps subtle differences in how the cell lines were 
maintained and grown.  In this context, others (Zampetaki, Xiao et al. 2006) have 
demonstrated that expression of TLR-4 varies in the D3 mES cell line and is regulated by 
epigenetic modifications. The state of chromatin in pluripotent ES cells is different from 
that of lineage committed cells (Sha et al.2009). The basic subunit of chromatin is the 
nucleosome, which is made up of two copies of the four core histones; H2A, H2B, H3 
and H4, wrapped around 147bp of DNA (Sha et al, 2009) and maybe different amongst 
different ES cell lines. The organization of the chromatin nucleosome can have local and 
global effects on DNA mediated processes including gene regulation (Figure 27). It has 
recently been shown that epigenetic changes can contribute to cell fate by reprogramming 
a somatic cell to an embryonic stem cell. Ectopic expression of key transcription factors: 
cMyc, Oct-4, Sox-2, and Nanog in differentiated cells has clearly demonstrated that the 
epigenome of a differentiated cell can be reprogrammed to support embryonic 
development (Martin 1981; Meissner, Wernig et al. 2007; Takahashi, Okita et al. 2007; 
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Takahashi, Tanabe et al. 2007; Aoi, Yae et al. 2008; Lowry, Richter et al. 2008; 
Nakagawa, Koyanagi et al. 2008; Park, Zhao et al. 2008; Wernig, Meissner et al. 2008; 
Yamanaka 2008).  
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Figure 27. The basic unit of chromatin organization includes the nucleosome, which is 
made up of 147bp of DNA wrapped around a histone protein. Figure adapted from (Sha 
et al, 2009) 
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Figure 27 
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                 It is thought that TLR-2 and TLR-4 are important for differentiation and self 
renewal of other types of stem cells (Nagai, Garrett et al. 2006). A recent report shows 
MSCs that are set to undergo differentiation in the presence of TLR-2 ligand stimulation 
remained in a non-differentiated state (Pevsner-Fischer, Morad et al. 2007). Most 
importantly, we have defined a new role for TLR-2 in the E14 mES cell line, and its 
ligand Pam3Cys on the E14 mES cell line. Pam3Cys enhanced proliferation and cell 
survival, and decreased apoptosis in LIF-cultured cells, without apparent changes in the 
immature phenotype of the cells as assessed by cell morphology, and expression of 
SSEA-1, Oct-4, KLF-4, Sox-2 and alkaline phosphatase.  
 
TLR-2 Pathway Activates NF-κB in mES cells 
NF-κB nuclear translocation as well as increased proliferation did not result from TLR-4 
ligand stimulation. We speculate that TLR-2 activation on mES cells may play a role in 
maintenance of the mES cell niche. Some of these effects may be, at least in part, 
mediated by translocation of NF-κB (Delhalle, Blasius et al. 2004; Liang, Zhou et al. 
2004), and events upstream of NF-κB, including phosphorylation of IKK-α/β, as well as 
downstream reflects such as enhanced protein expression of BCL-2, as well as 
induced/enhanced expression of mRNA for TNF- α, IFN-γ, and IL-6. These cytokines 
have many functional activities, including effects on the hematopoietic system (Delhalle, 
Blasius et al. 2004). Although we did not detect, within the limits of our ELISA assay, 
TNF-α, IL-6 nor IFN-β protein released into mES cell line containing culture medium in 
the presence or absence of Pam3Cys, if these three cytokines are having effects on 
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proliferation and/or survival of the E14 mES cell line, it would likely be through an 
autocrine-type interaction within the E14 cells, unless cytokine levels below that which 
we can detect are active, or working in synergy with each other and/or other released 
cytokines (Guo, Hangoc et al. 2005).   
             In contrast to the results of others (Lee, Hong et al. 2009) with the D3 mES cell 
line in which a large percentage of the cells expressed TLR-4, and LPS from E.coli 
modestly enhanced proliferation of these cells as detected by BrdU incorporation, our 
E14 mESC line showed no expression of TLR-4 on the cell surface, but responded to 
LPS from Salmonella with decreased cell survival and enhanced apoptosis. Whether this 
is mediated by TLR-4 or another TLR is not clear, but it did not appear to reflect nuclear 
translocation of NF-κB as noted in Figure 3 A-D. This does bring up caution in assuming 
that what occurs in one mES cell line will happen in another mES cell line. Again, this 
may reflect the mES cell itself, or how these cells are maintained in culture (Zampetaki, 
Xiao et al. 2006). It has recently been shown that “non-classical” LPS, such as that from 
bacteroides fragilis or any bacteria other than Escherichia coli, signals primarily through 
TLR-2 and not TLR-4 (Alhawi, Stewart et al. 2009). Classical LPS comes from 
Escherichia coli bacteria but in our studies we used LPS from Salmonella and this may 
be working through the TLR-2 receptor on the E14 mES cell line. Therefore, LPS maybe 
working through TLR-2 but functions to activate a pathway which causes apoptosis, 
where as Pam3Cys functions through the TLR-2 receptor and activates a pathway which 
cause proliferation of ES cells. This requires further investigation. Lastly our results with 
poly I:C (Figure 3 F), an activator of TLR-3, suggest that TLR-3 is functionally active in 
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the E14 mES cell line, as it is enhancing cell proliferation in the D3 mES cell line (Lee, 
Hong et al. 2009). In our case, we showed that PolyI:C enhanced/induced 
phosphorylation of IKKα/β.  
 
Differentiation Experiments 
In our study, we found that TLR-2 activation, by its ligand Pam3cys, may help to 
decrease differentiation of mES cells in the absence of LIF. However, these studies were 
not conclusive due to differing effects as assessed by Western blotting and flow 
cytometry. 
                Roles of TLRs on differentiation of HPCs have been reported in innate immune 
system replenishment by HPCs (Nagai, Garrett et al. 2006) and in regeneration of 
intestinal epithelia (Pull, Doherty et al. 2005). Further investigation of these processes 
will be needed to determine how signals delivered through the activation of TLRs 
influence stem cell differentiation. 
                In summary, we demonstrate that mES cells express functional TLR-2 and that 
the expression of TLR-2 may be involved in proliferation and survival of non-
differentiated mES cells. It is possible, but as yet unproven that activation of TLR-2 may 
helps mES cells remain in an un-differentiated state under differentiation inducing 
conditions, such as with removal of LIF. 
               Murine ES cell lines have been and continue to be useful models to study stem 
cell function and responsiveness to cytokines/ligands. Overall, this work is in agreement 
with the statement of others (Lee, Hong et al. 2009), that although the biological 
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significance of functional TLRs in mES cell lines are not yet known, further investigation 
of these cells could shed important and new information on the self-renewing, pluripotent 
state of ES cells that may translate into useful information for other stem cell types, and 
their modulation.  
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FUTURE DIRECTIONS 
 
Activation of Natural TLR-2 ligands on mESCs 
There are many unanswered questions. For example, what would be the natural ligand for 
TLR-2 on ES cells?  In our study we used one ligand, Pam3Cys, but there are other 
ligands for the TLR-2/TLR-6 hetrodimer. Peptidoglycan is a natural TLR-2 ligand (Lien, 
Sellati et al. 1999; Asong, Wolfert et al. 2009; Shida, Kiyoshima-Shibata et al. 2009). It 
activates TLR-2 through the TLR-2/TLR-6 heterodimer and has also been shown to cause 
an induction of NF-κB nuclear translocation in other cells, and may also be functional in 
mES cells because we show expression of TLR-2 and TLR-6 at the mRNA level (Figure 
5). We could also determine if TLR-6 is expressed on the surface of mES cells, when 
antibodies to TLR-6 become available. 
  
Effects of TLR2 activation on mES cells differentiation  
We did not perform self renewal colony assays on mESCs, and this can be done. Our 
attemps to determine if TLR-2 activation could block or prevent differentiation of the 
mES cells in the absence of LIF but in the presence of TLR-2 ligand was not conclusive. 
TLR-2 may be involved in helping to maintain the niche for ES cells self-renewal. We 
showed Oct-4 levels increase in the absence of LIF and that ERK phosphorylation 
decreased in mES cells in the absence of LIF but in the presence of TLR-2 ligand 
assessed by western blot, but our flow data showed little change in expression of Oct-4 
levels in the absence or presence of Pam3Cys but after removal of LIF (Figure 26). Since 
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ES cell differentiation to EBs results in the formation of a ball of cells, perhaps all the 
cells were not broken up in order to get an accurate readout of cellular and intracellular 
protein levels. In the future, we could also perform western blot experiments using other 
undifferentiated markers such as Nanog, Sox-2, and KLF-4 to determine if we see 
expression in Day6 EBs treated with Pam3Cys. 
 
Do other TLR-ligands influence differentiation of mES cells in the absence of LIF? 
We can evaluate this by further differentiating the cells in the absence of LIF and 
determining if they form more differentiated cells, such as an hemangioblast. Next, we 
can check for differentiation markers such as Brachuary and FLK-1 expression in these 
EBs as compared to cells not treated with TLR ligands. We could also determine effects 
on differentiation down the hematopoietic and endothelial cell lineages that derive from 
hemangioblast. 
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